暨南大学教授，生物活性分子与成药性优化全国重点实验室主任。曾获国家杰青、国家级领军人才，入选新世纪百千万人才工程国家级人选、英国皇家化学会会士、广东省重大人才计划杰出人才等，并获全国模范教师、全国优秀科技工作者称号。现兼任国家药典委员会委员、教育部科学技术委员会药学与中医药学部委员、世界中医药学会联合会中药化学专业委员会副会长、中国药学会中药和天然药物专业委员会副主任委员、广东省药学会理事长、《Engineering》杂志医药卫生学科执行主编等。

一直从事中药和天然药物活性成分及创新药物研究，以通讯作者在Chem、Nat Metab、Gut、JACS、ACIE、J Clin Invest、PNAS、Nat Commun等国际知名杂志发表SCI论文370余篇，H指数73，论文被引用2.67万次，连续11次入选Elsevier中国高被引学者榜单；获授权国内外发明专利120余项；研发新药多项，其中获一类新药证书1件、新药上市申请1件；获全国创新争先奖、中国药学发展奖、广东丁颖科技奖，以第一完成人获国家科技进步奖二等奖1项、广东省科学技术奖一等奖3项，并获中国产学研合作创新成果一等奖2项、中国专利优秀奖1项，研究成果入选“2017中国十大医学进展”。

主要研究方向：

       1. 天然生物活性分子高效发现技术研究
       2. 天然产物的化学生物学研究
       3. 源于中药和天然药物的创新药物研究

代表性论文：

       1 Song JG, Zheng J, Wei RJ, Huang YL, Jiang J, Ning GH, Wang Y*, Lu W*, Ye WC*, Li D*. Crystalline mate for structure elucidation of organic molecules.Chem, 2024, 10(3): 924-937.

       2 Wang CR, Huang MH, Lin YN, Zhang YM, Pan JH, Jiang C, Cheng MJ, Li SR, He WZ, Li ZQ, Tu ZC, Fan J, Zeng HH, Lin JH, Wang YJ, Yao N, Liu TZ, Qi Q, Liu XN, Zhang ZM, Chen MF*, Xia LP*, Zhang DM*, Ye WC*. ENO2-derived phosphoenolpyruvate functions as an endogenous inhibitor of HDAC1 and confers resistance to antiangiogenic therapy. Nature Metabolism, 2023, 5(10): 1765–1786.

       3 Wang S, Ye G, Xu X, Lin Y, Li X, Zhang Z, Qi M, Tan L, Cheng M, Zhang H, Pan J, Lin C, Huang D, Deng R, Li X, Wang G, Qiu S, Chu X, Chen Y, Zeng H, Zhang J, Wang C, Shuai H, Shi C, Yuan X, Cao Y*, Chen M*, Huang M*, Ye W*, Zhang D*. Pericyte drives the formation of circulating tumour cell-neutrophil clusters to promote colorectal cancer metastasis. Gut, 2026, 75(1), 81–93.

       4 Wang J, Song JG, Zhong DL, Duan ZZ, Peng ZJ, Tang W, Song QY, Huang XJ, Hu LJ*, Wang Y*, Ye WC*. Biomimetic synthesis of an antiviral cinnamoylphloroglucinol collection from Cleistocalyx operculatus: a synthetic strategy based on biogenetic building blocks. Angewandte Chemie-International Edition, 2023, 62(50), e202312568.

       5 He QF, Wu ZL, Li L, Sun WY, Wang GY, Jiang RW, Hu LJ, Shi L, He RR, Wang Y*, Ye WC*. Discovery of neuritogenic Securinega alkaloids from Flueggea suffruticosa by a building-block-based molecular network strategy. Angewandte Chemie-International Edition, 2021, 60, 19609.

       6 Cheng M-J, Wu Y-Y, Zeng H, Zhang T-H, Hu Y-X, Liu S-Y, Cui R-Q, Hu C-X, Zou Q-M, Li C-C, Ye W-C*, Huang W*, Wang L*. Asymmetric total synthesis of polycyclic xanthenes and discovery of a WalK activator active against MRSA. Nature Communications, 2024, 15(1), 5879.

       7 Yang C, Lei X, Chen X-B, Li N-P, Li B, He Y-X, Lin S-L, Chen M, Zhang T-H, Wang Y-H, Gao H, Li C-C*, Cheng M-J*, Ye W-C*, Wang L*. Bridged-Backbone Strategy Enables Asymmetric Synthesis of Highly Functionalized Oxabicyclo[3.3.1]nonanes with Anti-Osimertinib-Resistant NSCLC Activity. Journal of the American Chemical Society, 2025, 147(42), 38390–38403.

       8 Chen MF, Lei XP, Shi CZ, Huang MH, Li XB, Wu BJ, Li ZQ, Han WL, Du B, Hu JY, Nie QL, Mai WQ, Ma N, Xu NH, Zhang XY, Fan CL, Hong AH, Xia MH, Luo LP, Ma AD, Li HH, Yu Q, Chen HR*, Zhang DM*, Ye WC*. Pericyte-targeting prodrug overcomes tumor resistance to vascular disrupting agents. The Journal of Clinical Investigation, 2017, 127, 3689−3701.

       9 Zhang Y, Liu X, Weng L, Li S, Chen P, Zhang G, Wang J, Zhang D, Tang C, Hu Y, Ye W*, Zhang H*. Targeting the polyene chain represents an adjuvant strategy for optimizing polyene antifungals. Proceedings of the National Academy of Sciences, 2026, 123(17), e2534610123.

       10 Yao N, Wang CR, Liu MQ, Li YJ, Chen WM, Li ZQ, Qi Q, Lu J-J, Fan CL, Chen MF, Qi M, Li XB, Hong J, Zhang DM*, Ye WC*. Discovery of a novel EGFR ligand DPBA that degrades EGFR and suppresses EGFR-positive NSCLC growth. Signal Transduction and Targeted Therapy,2020,5, 214.

联系方式：

       E-mail: